Search

Search Constraints

You searched for: Author/Creator Carretero, G.

Search Results

1. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate‐to‐severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm. (6th June 2017)

2. Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. (15th July 2013)

3. Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry. (12th April 2017)

4. Cutaneous reactions after SARS‐CoV‐2 vaccination: a cross‐sectional Spanish nationwide study of 405 cases. (1st January 2022)

5. Cutaneous reactions after SARS‐CoV‐2 vaccination: a cross‐sectional Spanish nationwide study of 405 cases. (21st September 2021)

7. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate–severe psoriasis in Spain. BIOBADADERM registry. (8th November 2012)

8. One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate‐to‐severe plaque psoriasis. (February 2014)

9. One‐year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate‐to‐severe plaque psoriasis. (1st February 2014)

10. Real‐world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group. (17th June 2020)